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Objectives: To describe and compare the use and effectiveness of a single intra-articular
injection (IA) of triamcinolone acetonide (TA), hyaluronan (HA), and a combination of both
(TA+HA) in police working dogs with natural occurring hip osteoarthritis (OA).
Study Design: Prospective, randomized, single-blinded study.
Sample Population: Thirty animals with naturally occurring hip OA.
Methods: Animals were randomly divided in three groups: GT, treated with 20mg of
TA per hip joint; GH, treated with treated 20mg of HA per hip joint; and GTH, treated
with a combination of 20mg of TA and 20mg of HA per hip joint. Response to treatment,
measured by the Canine Brief Pain Inventory (divided in Pain Interference Score—PIS and
Pain Severity Score—PSS) and the Hudson Visual Analog Scale (HVAS), was evaluated
in seven different time points: T0 (before treatment), T1 (after 15 days), T2, T3, T4, T5,
and T6 (after 1, 2, 3, 4, and 5 months, respectively). Results were compared using a
Kruskal-Wallis test or a Wilcoxon signed ranks test, and p < 0.05 was set.
Results: Comparing results of the different time points considered with T0, significant
differences were registered in GH at T1 for HVAS (p = 0.03) and PIS (p = 0.04);
and in GTH at T1 (p = 0.05 for HVAS and p < 0.05 for PIS), T2 (p < 0.04
for PIS), T3 (p < 0.03 for HVAS and p = 0.05 for PIS), T4 (p < 0.03 for HVAS
and p < 0.05), and T5 (p < 0.05 for HVAS). No significant differences were found
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between groups when comparing scores in each time point. Individual treatment is
considered successful with a reduction of !1 for PSS or !2 for PIS. In GTH, treatment
was successful in four animals between T1 and T5 (40%, n = 10) and three at T6–T7
(30%, n = 10) for PSS and three animals of GTH at T1 (30%), two at T2 (20%), three
between T3 and T4 (30%), and two between T5 and T7 (20%).
Conclusions and Clinical Relevance: This study provides direct information on the
use of these treatment modalities in patients with hip OA. Intra-articular injection with
TA and HA may be a treatment option for dogs with naturally occurring OA, particularly
when simultaneously used, as they provide significant improvements of PIS and HVAS
scores. Individual scores improved in some animals with PIS, PSS, and HVAS.
Keywords: animal model, osteoarthritis, pain, triamcinolone, hyaluronan
INTRODUCTION
Osteoarthritis (OA) is a complex joint disease with a high
negative impact on patient’s quality of life and a high financial
burden. Characterized by its inflammatory character and
degradation of cartilage layers, it is a source of chronic pain,
which a!ects all mammals, including humans and dogs (1–3). In
adult active dogs, OA presents a prevalence around 20% (4–6).
This value is expected to rise, due to a simultaneous increase in
life expectancy and obesity. Both surgical and natural occurring
canine models have been widely studied, and since pathologic
process, clinical presentation and response to treatment are
very similar in both species—humans and dog, this animal
model is the closest to a gold standard (7–10). The changes
that occur in slowly progressive spontaneous dog OA closely
match those of human OA, in contrast with those seen in
rapidly advancing experimental surgical induced OA (11). The
grades of canine hip OA are similar to those in the classification
of human OA (mild/minimal, moderate, and severe) (12, 13).
In addition, companion animals share the same environment
and su!er similar co-morbidities as humans, with OA usually
being present for prolonged periods. Therefore, these naturally
occurring painful disease models may better reflect the complex
genetic, environmental, temporal, and physiological influences
present in humans (12). Exploring spontaneous dog OA under
the One Medicine concept can promote new insight on the
disease, improving therefore the health and well-being of both
species, humans, and dogs (12, 13).
Intra-articular (IA) corticosteroids (CS) have been used
for several decades in humans and horses to successfully
palliate pain and control inflammation associated with OA
and surrounding tissues (14, 15). Di!erent guidelines for
the management of human OA provide varying strength of
recommendation for the use of intra-articular CS, from weak
to strong recommendation (16–20). On the other hand, other
guidelines state an inability to recommend for or against the
use of intra-articular corticosteroids, in this case specifically
for patients with symptomatic knee OA (21). Corticosteroids
reduce the number of inflammatory cells such as lymphocytes,
macrophages and mast cells, and also slow down the synthesis of
inflammatory mediators such as interleukin 1!, Tumor necrosis
factor ", and Cycloxygenase 2 in the synovial fluid (22–25).
The pain relief they provide is attributed to the inhibition of
prostaglandin synthesis (24). Triamcinolone is recommended
over other CS due to an extended duration of action (26,
27). Hyaluronan (HA), the high molecular glycosaminoglycan,
occurs naturally in synovial fluid, and provides joint lubrication,
helps limit inflammation, pain and cartilage degradation while
acting as a shock absorber, allowing the joint to move in
a smooth manner (16, 17). Its mechanism of action is not
completely understood, but anti-inflammatory, anti-nociceptive,
and chondroprotective properties have been suggested, through
the enhancement of cartilage synthesis, blunting response to
interleukin 1, protection from the damage of oxygen free
radicals, and protection of chondrocytes from apoptosis (28–
31). Guidelines for the management of OA provide a weak
recommendation for the use of IA HA (20), a conditional
recommendation against (19) or that they should not be o!ered
as an option (18). The choice to use IAHA or a CS, or which CS to
use, is often determined by individual preference of the clinician
(18, 19). A popular approach is their combined administration,
thus providing rapid onset of action (obtained from the CS),
with prolonged e!ect and decreasing the potential side e!ects of
intra-articular CS therapy (obtained from HA) (20, 21). Being
an incurable chronic disease, treatment success in OA is often
defined as the ability to manage its symptoms, mainly pain.
The similarities in neurophysiology across mammals strongly
suggest that the type of pain experienced by humans and animals
is analogous (22). The Canine Brief Pain Inventory (CBPI)
was developed to assess the impact of chronic pain in the
patient’s life. It is divided in two sections, a pain severity score
(PSS) that assesses the magnitude of the animal’s pain, and a
pain interference score (PIS) that assesses the degree in which
pain a!ects daily activities (23). The Hudson Visual Analog
Scale (HVAS) has been validated for the assessment of mild
to moderate lameness in dogs, using force plate analysis as a
criterion-reference standard (24).
With this study, we aimed to determine (1) if the intra-
articular administration of triamcinolone acetonide (TA) or
HA can reduce pain scores in a naturally occurring canine
osteoarthritis model and if (2) the combined administration of
both substances provides better results for longer periods of time.
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METHODS
The study used a sample of 30 working dogs (N = 30) from the
Guarda Nacional Republicana (Portuguese Gendarmerie Canine
Unit) of both genders (6 females and 24 males), with a mean age
of 6 ± 2.4 years old and body weight of 33.3 ± 6.65 kg. Breeds
included German Shepherd Dogs (n = 20), Belgian Malinois
Shepherd Dogs (n = 5), Labrador Retriever (n = 4), and Dutch
Shepherd Dog (n = 1). All had bilateral naturally occurring mild
and moderate hip OA, classified according to the Orthopedic
Foundation for Animals scoring, This method was chosen due to
the unavailability of other evaluation methods, such as PennHip.
Radiographic evaluation was performed by one of the authors
(JCA), not a board radiologist but with extensive training and
experience in radiographic examination.
Patients were included based on trainer complaints, physical
examination, and standard pelvis radiographic evaluation
consistent with bilateral hip OA. Animals with other diseases
were ruled out through physical examination, complete blood
count, and basic serum chemistry profile (BUN, Creat, ALT,
AST, Gluc) were not included in the study. Patients under any
treatment, therapy or supplement were also excluded. Written,
informed consent was obtained from the Institution responsible
for the animals.
FIGURE 1 | Overall Pain Severity Scores, by section and instant for triamcinolone acetonide (TA), hyaluronan (HA), and TA+HA. Box plots represent median, 25th and
75th percentiles, and whiskers represent 10th and 90th percentiles. *indicates significant differences within the group, when compared with T0.
FIGURE 2 | Overall Pain Interference Scores, by section and instant for triamcinolone acetonide (TA), hyaluronan (HA), and TA+HA. Box plots represent median, 25th
and 75th percentiles, and whiskers represent 10th and 90th percentiles.
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Dogs were randomly divided in three groups according to
the type of drug used for hip joint IA administration, namely:
GT (treated with 20mg of TA per hip joint—Trigon depot,
Bristol-Myers Squibb R", Spain), GH (treated with 20mg of
hyaluronan per hip joint—Hyalart, Grunenthal R", Portugal), and
GTH (treated with the combination of both substances per hip
joint). Breeds were similarly distributed amongst groups: GT had
7 German Shepherd Dogs, 2 Belgian Malinois Shepherd Dog
and 1 Labrador Retriever; GH had 6 German Shepherd Dogs,
2 Belgian Malinois Shepherd Dogs, 1 Labrador Retriever and 1
Dutch Shepherd Dog; and GTH had 7 German Shepherd Dogs, 1
Belgian Malinois Shepherd Dogs and 2 Labrador Retrievers.
The IA administration was always made by the same
clinician and conducted with dogs under light sedation using
medetomidine (0.01 mg/kg) and buthorphanol (0.1 mg/kg),
both administered intravenously, and with intravenous fluids of
NaCl 0.9% in the dose of 2 ml/Kg/h. Animals were placed in
lateral recumbency, and a small window of 4 cm # 4 cm area
surrounding the greater trochanter was clipped and aseptically
prepared, using a chlorhexidine solution 0.2% followed by 70%
alcohol application, using sterile gloves and 10 cm # 10 cm
gauzes. With the limb parallel to the table surface and in a
neutral position, the operator inserted a 22-gauge with 75mm
length spinal needle, closely dorsal to the greater trochanter and
perpendicular to the long axis of the limb (32). Confirmation of
correct needle placement was obtained through the collection of
synovial fluid. Both hips were treated with the same treatment
in all animals. After treatment, animals were rested for 3
consecutive days. Signs of exacerbated pain during daily activities
or physical examination (pain during jointmobilization, sti!ness,
and reduced range of motion), persistent sti!ness of gait and
changes in posture exhibited by the dogs, were evaluated by the
veterinarian on the days 1 and 3 after the IA procedure. With
IA treatments, some side e!ects were documented, and include
local pain and inflammation, swelling and infection. These are
usually self-limiting, and take 2–10 days to resolve (33, 34). If no
complaints were registered, the animal could resume its normal
activity over a period of 5 days (35, 36).
To evaluate the response to treatment and comparing it with
the initial clinical condition, two validated tools for dog pain
assessment were used: the CBPI (Appendix A) and the HVAS
(Appendix B). These were completed by the trainers, who were
unaware of which treatment the animal received. Evaluations
were conducted at T0 (before IA treatment), T1 (15 days after IA
treatment), T2, T3, T4, T5, T6, and T7 (1, 2, 3, 4, 5, and 6 months
after IA treatment, respectively).
From all the sampled individuals, three dogs from the
GT were excluded—two after T2 due to having developed
unrelated medical conditions (one developed gastric dilatation
volvulus and the other su!ered a third phalanx avulsion),
and one after T3 due to an inability to maintain medical
follow-up. Data collected from these animals was considered
up to the point of their exclusion. Data was analyzed
with IBM SPSS Statistics version 20, and a significance
level of p < 0.05 was set. Normality was accessed with
a Shapiro-Wilk test and results of all groups in each time
point considered were compared using a Kruskal-Wallis test.
When comparing each time point with T0 within each
FIGURE 3 | Overall Hudson Visual Analog scores, by instant for triamcinolone acetonide (TA), hyaluronan (HA), and TA+HA. Box plots represent median, 25th and
75th percentiles, and whiskers represent 10th and 90th percentiles. *indicates significant differences within the group, when compared with T0.
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group, a Kruskal-Wallis test or a Wilcoxon signed ranks test
was used.
RESULTS
InGT, when comparing clinical results fromT1 to T7with patient
initial condition (T0), no significant di!erences were recorded.
In GH, significant di!erences were observed only at T1 (p= 0.03
for HVAS and p = 0.04 for PSS). In GTH, significant di!erences
were observed at T1 (p < 0.05 for HVAS and p < 0.05 for PSS),
T2 (p < 0.04 for PSS), T3 (p < 0.03 for HVAS and p < 0.05
for PSS), T4 (p < 0.03 for HVAS and p < 0.05 PSS), and T5
(p < 0.05 for HVAS). Comparing results of the three groups in
each evaluation moment, no significant di!erences were found.
Evolution of PSS, PIS, and HVAS scores can be observed in
Figures 1–3, respectively. Evolution of mean PSS, PIS, and HVAS
scores (±standard deviation), p values and percentage variations
in each group, are presented in Table 1.
During the study, no side e!ects were detected in any of
the animals. All patients were able to resume normal activity
after treatment.
DISCUSSION
OA is a chronic disease with no cure, but with the possibility to
be e!ectively managed in a largely palliative approach, aiming
to relieve symptoms and especially pain (17, 29). Non-steroidal
anti-inflammatory drugs (NSAIDs) are often considered as
the first line of OA treatment. For active patients, or with
more advanced OA stages, the control they provide over signs
and symptoms may be insu"cient (30, 31, 37). Since OA is
symptomatic only in the a!ected joint, while lacking obvious
extra-articular manifestations, it is well-suited to have a local
therapy administered by intra-articular injection, reducing the
total amount required to produce an e!ect, compared with a
systemic administration (38–40). Still, this approach presents
some disadvantages, as the need of a precise diagnosis, the
learning curve inherent to the execution of the procedure
(particularly when considering hips), better conducted with the
assistance of fluoroscopy or ultrasound, and the need of placing
the patient under sedation or general anesthesia. Results showed
that both TA and HA, when administered through intra-articular
injection, are able to reduce pain levels to some degree and up to
certain time points, in a naturally occurring canine osteoarthritis
model. The combination of both substances, in particular, can be
an e!ective therapeutic option, with a majority of treated patients
showing improved results in their clinical condition, lasting for
several months.
Limitations of this study are associated with sample size and
the lack of a control group. Additionally, even though both the
CBPI andHVAS have been validated as tools for the assessment of
pain, lameness, and response to treatment in dogs, further studies
should include another evaluation method such as Force Plait
Gait or Stance Analysis.
The CBPI is often the analysis of choice in the veterinary
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groups (41, 42). In this study, significant variations were observed
in GH only at the first follow up, and for PSS. In GTH,
improvements were also observed in PSS scores, but for a
longer period. It was in GTH that the biggest improvement was
observed, with a 44.7% improvement at T3. Individual treatment
success has been set as a decrease in PSS ! 1 and in PIS ! 2 (28,
43). Both IA treatments withHA and TAwere able to significantly
reduce individual scores in naturally occurring canine OAmodel,
particularly PSS, while improving the results for the majority
of patients. In some cases of GT and in one patient of GH,
beneficial results spread up to the last evaluation point, while
most improvements in both groups declined around T4-T5.
Results for PIS showed no significant variations, considering
group results. Individual results registered some improvements,
but less marked than PSS results. This may be because, for
some patients, PIS scores were low to begin with, making it
di"cult to reach a significant reduction. In addition, these are
dogs with very high prey drive and work motivation, which
may lead to a good performance and low perception of pain
interference during daily activities. Individual HVAS results
improved in almost all animals. However, when considering
group results, significant improvements were observed only
in GH (at T1) and GTH, in this case up to T5. In GTH,
similarly to PSS scores, improvements reached a highest of
25.5% at T3, and declined from this point, reaching an 18.2%
improvement at T5. The IA use of HA for the treatment of
OA is still somewhat controversial due to its mode of action
being unclear and clinical trials have provided contradictory
results (38). The results of our study showed improvements in
some animals at T1, with the maximal number of significant
improvements obtained at T2, and maintained for a couple
of months. Additional administrations, compared to a single
injection, may be required in order to obtain sustained results. IA
CS have been used for several decades in humans to successfully
palliate pain and control inflammation associated with OA and
surrounding tissues (14, 15). A systematic review has deemed
triamcinolone more e!ective in relieving pain and improving
function than betamethasone and methylprednisolone acetate
(44). The choice to use IA HA or CS, or which CS to use, is often
determined by individual preference of the clinician (18, 19).
There are reports presenting deleterious e!ects of IA CS, as
they may induce the production of a low quantity and high
viscosity synovial fluid. These results are often based on multiple
injections, particularly of methylprednisolone, while a single dose
does not seem to cause long-term detrimental e!ects (45, 46).
In a canine model of OA, animals treated with IA triamcinolone
showed a significant reduction of osteophyte size compared with
a control group. At the histological level, it significantly reduced
the severity of OA structural changes of cartilage and had no
deleterious e!ects on normal cartilage (47). Our results show
that a single IA TA is e!ective in reducing pain scores in some
animals, but not the majority of them. For those that it was,
benefits were detected for several months, in some cases up
to the last evaluation point. We did not observed any clinical
side-e!ects in the animals treated with TA, and this seems to
be a safe therapeutic options in patients with hip OA. As we
did not performed a follow-up radiographic evaluation of the
joints, we cannot comment on the evolution of radiographic signs
in the three considered groups, but it should be addressed in
future studies.
Results observed in GTH support the hypothesis that
combined administration of HA and TA is superior in positive
e!ects when comparing to the individual use of each one. PSS
scores show significant improvements until T3, raising from
a 25.3% at T1 to a 44.7% improvement at T3. Individual
PSS scores improved in several patients up to the six-month
evaluation point. HVAS in GTH also improved significantly
from T1 to T5, in contrast to what was observed in GT and
GH. This result is in accordance with what was observed
with PIS, reflecting increased mobility, presumably due to
decreased pain.
According to the author’s knowledge, this is the first study
that presents the description of the clinical e!ect of IA CS,
HA and the combined use of both products in a naturally
occurring canine model. The study was able to establish
that all therapeutic approaches are safe, since no side e!ects
were observed after the IA procedure in all animals of
the three groups considered. All treatments can be e!ective
for the treatment of OA, particularly the combined use of
both products (TA + HA). Future studies should enroll a




Intra-articular administration of TA and HA may be a
treatment option for natural occurring OA, particularly
when used simultaneously. This study provides information
on the use of these treatment modalities in patients with
hip OA. Further studies are required, involving a larger
number of patients and the use of a more objective
evaluation method.
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